Skip to content
OpenCapital
Get started

Kodiak Sciences Inc KOD Current ratio

Current ratio at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
3.6×-1.4×
HRO
HarrowHROW
2.5×+1.6×
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
15.1×-4.3×
Ocular Therapeutix logo
Ocular TherapeutixOCUL
14.8×+4.6×
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
9×+0.6×
Vera Therapeutics logo
Vera TherapeuticsVERA
13.6×-14.0×

Other financials

Income statement

See full
Operating income-$59.8M-1.2%
Net income-$58.2M-1.2%
EPS (diluted)-$0.94+13.8%

Balance sheet

See full
Cash & equivalents$169.5M+22.1%
Total debt$56.0M-17.2%
Total equity$112.1M+3.0%
Total assets$306.0M+2.7%

Cash flow

See full
Operating cash flow-$40.0M-37.6%
CapEx$942.0K+249%
Free cash flow-$41.0M-39.5%

Valuation

See full
Market cap$2.32B+1,477%
Enterprise value$2.2B+2,798%

Returns & leverage

See full
Return on equity-208.8%+2,306pp
Debt / equity0.5×-0.1×

Where this comes from

Calculated from Kodiak Sciences Inc’s reported figures.

total current assets/total current liabilities=3.5×

Based on the most recent quarter.

The official record: Kodiak Sciences Inc’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kodiak Sciences Inc's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kodiak Sciences Inc's current ratio?
Kodiak Sciences Inc (KOD) reported current ratio of 3.5× in Q1 2026.
How has Kodiak Sciences Inc's current ratio changed year-over-year?
Kodiak Sciences Inc's current ratio decreased by 23.5% year-over-year, from 4.6× to 3.5×.
What is the long-term trend for Kodiak Sciences Inc's current ratio?
Over 5 years (2020 to 2025), Kodiak Sciences Inc's current ratio has grown at a -31.3% compound annual growth rate (CAGR), from 30.9× to 4.7×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.